These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34253738)

  • 1. Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition.
    Zhao N; Powell RT; Yuan X; Bae G; Roarty KP; Stossi F; Strempfl M; Toneff MJ; Johnson HL; Mani SA; Jones P; Stephan CC; Rosen JM
    Nat Commun; 2021 Jul; 12(1):4262. PubMed ID: 34253738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
    Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
    Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the tumour transition states occurring during EMT.
    Pastushenko I; Brisebarre A; Sifrim A; Fioramonti M; Revenco T; Boumahdi S; Van Keymeulen A; Brown D; Moers V; Lemaire S; De Clercq S; Minguijón E; Balsat C; Sokolow Y; Dubois C; De Cock F; Scozzaro S; Sopena F; Lanas A; D'Haene N; Salmon I; Marine JC; Voet T; Sotiropoulou PA; Blanpain C
    Nature; 2018 Apr; 556(7702):463-468. PubMed ID: 29670281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.
    Shi Z; Zhang J; Qian X; Han L; Zhang K; Chen L; Liu J; Ren Y; Yang M; Zhang A; Pu P; Kang C
    Cancer Res; 2013 Sep; 73(17):5519-31. PubMed ID: 23811941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.
    Fifis T; Nguyen L; Malcontenti-Wilson C; Chan LS; Nunes Costa PL; Daruwalla J; Nikfarjam M; Muralidharan V; Waltham M; Thompson EW; Christophi C
    Cancer Med; 2013 Oct; 2(5):595-610. PubMed ID: 24403226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.
    Li Q; Chen C; Kapadia A; Zhou Q; Harper MK; Schaack J; LaBarbera DV
    J Biomol Screen; 2011 Feb; 16(2):141-54. PubMed ID: 21297102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.
    Zhang N; Liu Y; Wang Y; Zhao M; Tu L; Luo F
    Drug Des Devel Ther; 2017; 11():969-983. PubMed ID: 28405157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.
    Johansson J; Berg T; Kurzejamska E; Pang MF; Tabor V; Jansson M; Roswall P; Pietras K; Sund M; Religa P; Fuxe J
    Oncogene; 2013 Dec; 32(50):5614-24. PubMed ID: 23955085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.
    Dunlap SM; Chiao LJ; Nogueira L; Usary J; Perou CM; Varticovski L; Hursting SD
    Cancer Prev Res (Phila); 2012 Jul; 5(7):930-42. PubMed ID: 22588949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
    Norkin M; Ordóñez-Morán P; Huelsken J
    Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
    Huang RY; Kuay KT; Tan TZ; Asad M; Tang HM; Ng AH; Ye J; Chung VY; Thiery JP
    Oncotarget; 2015 Sep; 6(26):22098-113. PubMed ID: 26061747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma.
    Chua KN; Sim WJ; Racine V; Lee SY; Goh BC; Thiery JP
    PLoS One; 2012; 7(3):e33183. PubMed ID: 22432005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells.
    Ahmad A; Sarkar SH; Bitar B; Ali S; Aboukameel A; Sethi S; Li Y; Bao B; Kong D; Banerjee S; Padhye SB; Sarkar FH
    Mol Cancer Ther; 2012 Oct; 11(10):2193-201. PubMed ID: 22821148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.